Global Immune Checkpoint Inhibitors Sales Market Report 2021

1 Immune Checkpoint Inhibitors Market Overview

• 1.1 Immune Checkpoint Inhibitors Product Scope
• 1.2 Immune Checkpoint Inhibitors Segment by Type
  • 1.2.1 Global Immune Checkpoint Inhibitors Sales by Type (2016 & 2021 & 2027)
  • 1.2.2 PD-1/PD-L1
  • 1.2.3 CTLA-4
• 1.3 Immune Checkpoint Inhibitors Segment by Application
  • 1.3.1 Global Immune Checkpoint Inhibitors Sales Comparison by Application (2016 & 2021 & 2027)
  • 1.3.2 Lung Cancer
  • 1.3.3 Colorectal Cancer
  • 1.3.4 Breast Cancer
  • 1.3.5 Prostate Cancer
  • 1.3.6 Melanoma
  • 1.3.7 Blood Cancer
  • 1.3.8 Other
• 1.4 Immune Checkpoint Inhibitors Market Estimates and Forecasts (2016-2027)
  • 1.4.1 Global Immune Checkpoint Inhibitors Market Size in Value Growth Rate (2016-2027)
  • 1.4.2 Global Immune Checkpoint Inhibitors Market Size in Volume Growth Rate (2016-2027)
  • 1.4.3 Global Immune Checkpoint Inhibitors Price Trends (2016-2027)

2 Immune Checkpoint Inhibitors Estimates and Forecasts by Region

• 2.1 Global Immune Checkpoint Inhibitors Market Size by Region: 2016 VS 2021 VS 2027
• 2.2 Global Immune Checkpoint Inhibitors Retrospective Market Scenario by Region (2016-2021)
  • 2.2.1 Global Immune Checkpoint Inhibitors Sales Market Share by Region (2016-2021)
  • 2.2.2 Global Immune Checkpoint Inhibitors Revenue Market Share by Region (2016-2021)
• 2.3 Global Immune Checkpoint Inhibitors Market Estimates and Forecasts by Region (2022-2027)
  • 2.3.1 Global Immune Checkpoint Inhibitors Sales Estimates and Forecasts by Region (2022-2027)
  • 2.3.2 Global Immune Checkpoint Inhibitors Revenue Forecast by Region (2022-2027)
• 2.4 Geographic Market Analysis: Market Facts & Figures
  • 2.4.1 North America Immune Checkpoint Inhibitors Estimates and Projections (2016-2027)
  • 2.4.2 Europe Immune Checkpoint Inhibitors Estimates and Projections (2016-2027)
  • 2.4.3 China Immune Checkpoint Inhibitors Estimates and Projections (2016-2027)
  • 2.4.4 Japan Immune Checkpoint Inhibitors Estimates and Projections (2016-2027)
  • 2.4.5 Southeast Asia Immune Checkpoint Inhibitors Estimates and Projections (2016-2027)
  • 2.4.6 India Immune Checkpoint Inhibitors Estimates and Projections (2016-2027)

3 Global Immune Checkpoint Inhibitors Competition Landscape by Players

• 3.1 Global Top Immune Checkpoint Inhibitors Players by Sales (2016-2021)
• 3.2 Global Top Immune Checkpoint Inhibitors Players by Revenue (2016-2021)
• 3.3 Global Immune Checkpoint Inhibitors Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Immune Checkpoint Inhibitors as of 2020)
• 3.4 Global Immune Checkpoint Inhibitors Average Price by Company (2016-2021)
• 3.5 Manufacturers Immune Checkpoint Inhibitors Manufacturing Sites, Area Served, Product Type
• 3.6 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Global Immune Checkpoint Inhibitors Market Size by Type

• 4.1 Global Immune Checkpoint Inhibitors Historic Market Review by Type (2016-2021)
  • 4.1.1 Global Immune Checkpoint Inhibitors Sales Market Share by Type (2016-2021)
  • 4.1.2 Global Immune Checkpoint Inhibitors Revenue Market Share by Type (2016-2021)
  • 4.1.3 Global Immune Checkpoint Inhibitors Price by Type (2016-2021)
• 4.2 Global Immune Checkpoint Inhibitors Market Estimates and Forecasts by Type (2022-2027)
  • 4.2.1 Global Immune Checkpoint Inhibitors Sales Forecast by Type (2022-2027)
  • 4.2.2 Global Immune Checkpoint Inhibitors Revenue Forecast by Type (2022-2027)
  • 4.2.3 Global Immune Checkpoint Inhibitors Price Forecast by Type (2022-2027)

5 Global Immune Checkpoint Inhibitors Market Size by Application

• 5.1 Global Immune Checkpoint Inhibitors Historic Market Review by Application (2016-2021)
  • 5.1.1 Global Immune Checkpoint Inhibitors Sales Market Share by Application (2016-2021)
  • 5.1.2 Global Immune Checkpoint Inhibitors Revenue Market Share by Application (2016-2021)
  • 5.1.3 Global Immune Checkpoint Inhibitors Price by Application (2016-2021)
• 5.2 Global Immune Checkpoint Inhibitors Market Estimates and Forecasts by Application (2022-2027)
  • 5.2.1 Global Immune Checkpoint Inhibitors Sales Forecast by Application (2022-2027)
  • 5.2.2 Global Immune Checkpoint Inhibitors Revenue Forecast by Application (2022-2027)
  • 5.2.3 Global Immune Checkpoint Inhibitors Price Forecast by Application (2022-2027)

6 North America Immune Checkpoint Inhibitors Market Facts & Figures

• 6.1 North America Immune Checkpoint Inhibitors Sales by Company
  • 6.1.1 North America Immune Checkpoint Inhibitors Sales by Company (2016-2021)
  • 6.1.2 North America Immune Checkpoint Inhibitors Revenue by Company (2016-2021)
• 6.2 North America Immune Checkpoint Inhibitors Sales Breakdown by Type
  • 6.2.1 North America Immune Checkpoint Inhibitors Sales Breakdown by Type (2016-2021)
  • 6.2.2 North America Immune Checkpoint Inhibitors Sales Breakdown by Type (2022-2027)
• 6.3 North America Immune Checkpoint Inhibitors Sales Breakdown by Application
  • 6.3.1 North America Immune Checkpoint Inhibitors Sales Breakdown by Application (2016-2021)
  • 6.3.2 North America Immune Checkpoint Inhibitors Sales Breakdown by Application (2022-2027)

7 Europe Immune Checkpoint Inhibitors Market Facts & Figures

• 7.1 Europe Immune Checkpoint Inhibitors Sales by Company
  • 7.1.1 Europe Immune Checkpoint Inhibitors Sales by Company (2016-2021)
  • 7.1.2 Europe Immune Checkpoint Inhibitors Revenue by Company (2016-2021)
• 7.2 Europe Immune Checkpoint Inhibitors Sales Breakdown by Type
  • 7.2.1 Europe Immune Checkpoint Inhibitors Sales Breakdown by Type (2016-2021)
  • 7.2.2 Europe Immune Checkpoint Inhibitors Sales Breakdown by Type (2022-2027)
• 7.3 Europe Immune Checkpoint Inhibitors Sales Breakdown by Application
  • 7.3.1 Europe 143 Sales Breakdown by Application (2016-2021)
  • 7.3.2 Europe 143 Sales Breakdown by Application (2022-2027)

8 China Immune Checkpoint Inhibitors Market Facts & Figures

• 8.1 China Immune Checkpoint Inhibitors Sales by Company
  • 8.1.1 China Immune Checkpoint Inhibitors Sales by Company (2016-2021)
  • 8.1.2 China Immune Checkpoint Inhibitors Revenue by Company (2016-2021)
• 8.2 China Immune Checkpoint Inhibitors Sales Breakdown by Type
  • 8.2.1 China Immune Checkpoint Inhibitors Sales Breakdown by Type (2016-2021)
  • 8.2.2 China Immune Checkpoint Inhibitors Sales Breakdown by Type (2022-2027)
• 8.3 China Immune Checkpoint Inhibitors Sales Breakdown by Application
  • 8.3.1 China 166 Sales Breakdown by Application (2016-2021)
  • 8.3.2 China 166 Sales Breakdown by Application (2022-2027)

9 Japan Immune Checkpoint Inhibitors Market Facts & Figures

• 9.1 Japan Immune Checkpoint Inhibitors Sales by Company
  • 9.1.1 Japan Immune Checkpoint Inhibitors Sales by Company (2016-2021)
  • 9.1.2 Japan Immune Checkpoint Inhibitors Revenue by Company (2016-2021)
• 9.2 Japan Immune Checkpoint Inhibitors Sales Breakdown by Type
  • 9.2.1 Japan Immune Checkpoint Inhibitors Sales Breakdown by Type (2016-2021)
  • 9.2.2 Japan Immune Checkpoint Inhibitors Sales Breakdown by Type (2022-2027)
• 9.3 Japan Immune Checkpoint Inhibitors Sales Breakdown by Application
  • 9.3.1 Japan Mar. Sales Breakdown by Application (2016-2021)
  • 9.3.2 Japan Mar. Sales Breakdown by Application (2022-2027)

10 Southeast Asia Immune Checkpoint Inhibitors Market Facts & Figures

• 10.1 Southeast Asia Immune Checkpoint Inhibitors Sales by Company
  • 10.1.1 Southeast Asia Immune Checkpoint Inhibitors Sales by Company (2016-2021)
  • 10.1.2 Southeast Asia Immune Checkpoint Inhibitors Revenue by Company (2016-2021)
• 10.2 Southeast Asia Immune Checkpoint Inhibitors Sales Breakdown by Type
  • 10.2.1 Southeast Asia Immune Checkpoint Inhibitors Sales Breakdown by Type (2016-2021)
  • 10.2.2 Southeast Asia Immune Checkpoint Inhibitors Sales Breakdown by Type (2022-2027)
• 10.3 Southeast Asia Immune Checkpoint Inhibitors Sales Breakdown by Application
  • 10.3.1 Southeast Asia MT Sales Breakdown by Application (2016-2021)
  • 10.3.2 Southeast Asia MT Sales Breakdown by Application (2022-2027)

11 India Immune Checkpoint Inhibitors Market Facts & Figures

• 11.1 India Immune Checkpoint Inhibitors Sales by Company
  • 11.1.1 India Immune Checkpoint Inhibitors Sales by Company (2016-2021)
  • 11.1.2 India Immune Checkpoint Inhibitors Revenue by Company (2016-2021)
• 11.2 India Immune Checkpoint Inhibitors Sales Breakdown by Type
  • 11.2.1 India Immune Checkpoint Inhibitors Sales Breakdown by Type (2016-2021)
  • 11.2.2 India Immune Checkpoint Inhibitors Sales Breakdown by Type (2022-2027)
• 11.3 India Immune Checkpoint Inhibitors Sales Breakdown by Application
  • 11.3.1 India Immune Checkpoint Inhibitors Sales Breakdown by Application (2016-2021)
  • 11.3.2 India Immune Checkpoint Inhibitors Sales Breakdown by Application (2022-2027)

12 Company Profiles and Key Figures in Immune Checkpoint Inhibitors Business

• 12.1 Bristol Myer Squibb
  • 12.1.1 Bristol Myer Squibb Corporation Information
  • 12.1.2 Bristol Myer Squibb Business Overview
  • 12.1.3 Bristol Myer Squibb Immune Checkpoint Inhibitors Sales, Revenue and Gross Margin (2016-2021)
  • 12.1.4 Bristol Myer Squibb Immune Checkpoint Inhibitors Products Offered
  • 12.1.5 Bristol Myer Squibb Recent Development
• 12.2 AstraZeneca
  • 12.2.1 AstraZeneca Corporation Information
  • 12.2.2 AstraZeneca Business Overview
  • 12.2.3 AstraZeneca Immune Checkpoint Inhibitors Sales, Revenue and Gross Margin (2016-2021)
  • 12.2.4 AstraZeneca Immune Checkpoint Inhibitors Products Offered
  • 12.2.5 AstraZeneca Recent Development
• 12.3 Merck & Co.
  • 12.3.1 Merck & Co. Corporation Information
  • 12.3.2 Merck & Co. Business Overview
  • 12.3.3 Merck & Co. Immune Checkpoint Inhibitors Sales, Revenue and Gross Margin (2016-2021)
  • 12.3.4 Merck & Co. Immune Checkpoint Inhibitors Products Offered
  • 12.3.5 Merck & Co. Recent Development
• 12.4 Roche / Genentech
  • 12.4.1 Roche / Genentech Corporation Information
  • 12.4.2 Roche / Genentech Business Overview
  • 12.4.3 Roche / Genentech Immune Checkpoint Inhibitors Sales, Revenue and Gross Margin (2016-2021)
  • 12.4.4 Roche / Genentech Immune Checkpoint Inhibitors Products Offered
  • 12.4.5 Roche / Genentech Recent Development
• 12.5 Incyte Corporation
  • 12.5.1 Incyte Corporation Corporation Information
  • 12.5.2 Incyte Corporation Business Overview
  • 12.5.3 Incyte Corporation Immune Checkpoint Inhibitors Sales, Revenue and Gross Margin (2016-2021)
  • 12.5.4 Incyte Corporation Immune Checkpoint Inhibitors Products Offered
  • 12.5.5 Incyte Corporation Recent Development
• 12.6 NewLink Genetics
  • 12.6.1 NewLink Genetics Corporation Information
  • 12.6.2 NewLink Genetics Business Overview
  • 12.6.3 NewLink Genetics Immune Checkpoint Inhibitors Sales, Revenue and Gross Margin (2016-2021)
  • 12.6.4 NewLink Genetics Immune Checkpoint Inhibitors Products Offered
  • 12.6.5 NewLink Genetics Recent Development
• 12.7 ArGEN-X
  • 12.7.1 ArGEN-X Corporation Information
  • 12.7.2 ArGEN-X Business Overview
  • 12.7.3 ArGEN-X Immune Checkpoint Inhibitors Sales, Revenue and Gross Margin (2016-2021)
  • 12.7.4 ArGEN-X Immune Checkpoint Inhibitors Products Offered
  • 12.7.5 ArGEN-X Recent Development
• 12.8 Seattle Genetics
  • 12.8.1 Seattle Genetics Corporation Information
  • 12.8.2 Seattle Genetics Business Overview
  • 12.8.3 Seattle Genetics Immune Checkpoint Inhibitors Sales, Revenue and Gross Margin (2016-2021)
  • 12.8.4 Seattle Genetics Immune Checkpoint Inhibitors Products Offered
  • 12.8.5 Seattle Genetics Recent Development
• 12.9 Pfizer
  • 12.9.1 Pfizer Corporation Information
  • 12.9.2 Pfizer Business Overview
  • 12.9.3 Pfizer Immune Checkpoint Inhibitors Sales, Revenue and Gross Margin (2016-2021)
  • 12.9.4 Pfizer Immune Checkpoint Inhibitors Products Offered
  • 12.9.5 Pfizer Recent Development
• 12.10 MacroGenics
  • 12.10.1 MacroGenics Corporation Information
  • 12.10.2 MacroGenics Business Overview
  • 12.10.3 MacroGenics Immune Checkpoint Inhibitors Sales, Revenue and Gross Margin (2016-2021)
  • 12.10.4 MacroGenics Immune Checkpoint Inhibitors Products Offered
  • 12.10.5 MacroGenics Recent Development
• 12.11 Celldex Therapeutics
  • 12.11.1 Celldex Therapeutics Corporation Information
  • 12.11.2 Celldex Therapeutics Business Overview
  • 12.11.3 Celldex Therapeutics Immune Checkpoint Inhibitors Sales, Revenue and Gross Margin (2016-2021)
  • 12.11.4 Celldex Therapeutics Immune Checkpoint Inhibitors Products Offered
  • 12.11.5 Celldex Therapeutics Recent Development
• 12.12 CureTech
  • 12.12.1 CureTech Corporation Information
  • 12.12.2 CureTech Business Overview
  • 12.12.3 CureTech Immune Checkpoint Inhibitors Sales, Revenue and Gross Margin (2016-2021)
  • 12.12.4 CureTech Immune Checkpoint Inhibitors Products Offered
  • 12.12.5 CureTech Recent Development
• 12.13 Immutep
  • 12.13.1 Immutep Corporation Information
  • 12.13.2 Immutep Business Overview
  • 12.13.3 Immutep Immune Checkpoint Inhibitors Sales, Revenue and Gross Margin (2016-2021)
  • 12.13.4 Immutep Immune Checkpoint Inhibitors Products Offered
  • 12.13.5 Immutep Recent Development
• 12.14 Innate Pharma
  • 12.14.1 Innate Pharma Corporation Information
  • 12.14.2 Innate Pharma Business Overview
  • 12.14.3 Innate Pharma Immune Checkpoint Inhibitors Sales, Revenue and Gross Margin (2016-2021)
  • 12.14.4 Innate Pharma Immune Checkpoint Inhibitors Products Offered
  • 12.14.5 Innate Pharma Recent Development
• 12.15 Sorrento Therapeutics
  • 12.15.1 Sorrento Therapeutics Corporation Information
  • 12.15.2 Sorrento Therapeutics Business Overview
  • 12.15.3 Sorrento Therapeutics Immune Checkpoint Inhibitors Sales, Revenue and Gross Margin (2016-2021)
  • 12.15.4 Sorrento Therapeutics Immune Checkpoint Inhibitors Products Offered
  • 12.15.5 Sorrento Therapeutics Recent Development
• 12.16 GlaxoSmithKline
  • 12.16.1 GlaxoSmithKline Corporation Information
  • 12.16.2 GlaxoSmithKline Business Overview
  • 12.16.3 GlaxoSmithKline Immune Checkpoint Inhibitors Sales, Revenue and Gross Margin (2016-2021)
  • 12.16.4 GlaxoSmithKline Immune Checkpoint Inhibitors Products Offered
  • 12.16.5 GlaxoSmithKline Recent Development
• 12.17 GITR, Inc
  • 12.17.1 GITR, Inc Corporation Information
  • 12.17.2 GITR, Inc Business Overview
  • 12.17.3 GITR, Inc Immune Checkpoint Inhibitors Sales, Revenue and Gross Margin (2016-2021)
  • 12.17.4 GITR, Inc Immune Checkpoint Inhibitors Products Offered
  • 12.17.5 GITR, Inc Recent Development

13 Immune Checkpoint Inhibitors Manufacturing Cost Analysis

• 13.1 Immune Checkpoint Inhibitors Key Raw Materials Analysis
  • 13.1.1 Key Raw Materials
  • 13.1.2 Key Raw Materials Price Trend
  • 13.1.3 Key Suppliers of Raw Materials
• 13.2 Proportion of Manufacturing Cost Structure
• 13.3 Manufacturing Process Analysis of Immune Checkpoint Inhibitors
• 13.4 Immune Checkpoint Inhibitors Industrial Chain Analysis

14 Marketing Channel, Distributors and Customers

• 14.1 Marketing Channel
• 14.2 Immune Checkpoint Inhibitors Distributors List
• 14.3 Immune Checkpoint Inhibitors Customers

15 Market Dynamics

• 15.1 Immune Checkpoint Inhibitors Market Trends
• 15.2 Immune Checkpoint Inhibitors Drivers
• 15.3 Immune Checkpoint Inhibitors Market Challenges
• 15.4 Immune Checkpoint Inhibitors Market Restraints

16 Research Findings and Conclusion

17 Appendix

• 17.1 Research Methodology
  • 17.1.1 Methodology/Research Approach
  • 17.1.2 Data Source
• 17.2 Author List